EGFR and non-small cell lung carcinoma: Cetuximab-functionalized oriented MNPs by the current immobilization strategy achieved a 4.7-6-fold enhancement in EGFR pulldown efficiency from human embryonic kidney (HEK293T) and non-small cell lung cancer (NSCLC) models, compared to randomly immobilized controls.